MAIA Biotechnology Inc. (NYSE MKT:MAIA) — Market Cap & Net Worth
Market Cap & Net Worth: MAIA Biotechnology Inc. (MAIA)
MAIA Biotechnology Inc. (NYSE MKT:MAIA) has a market capitalization of $77.66 Million ($77.66 Million) as of July 23, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #20161 globally and #4538 in its home market, demonstrating a -5.88% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MAIA Biotechnology Inc.'s stock price $1.28 by its total outstanding shares 60671491 (60.67 Million). Review MAIA total debt and obligations to assess the company's total debt and financial obligations.
MAIA Biotechnology Inc. Market Cap History: 2022 to 2026
MAIA Biotechnology Inc.'s market capitalization history from 2022 to 2026. Data shows change from $212.96 Million to $77.66 Million (-27.88% CAGR).
MAIA Biotechnology Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MAIA Biotechnology Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MAIA by Market Capitalization
Companies near MAIA Biotechnology Inc. in the global market cap rankings as of July 23, 2026.
Key companies related to MAIA Biotechnology Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #425 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #544 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $472.57 |
| #425 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $651.18 |
| #544 | Argen-X | BR:ARGX | $49.55 Billion | €758.40 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €243.30 |
MAIA Biotechnology Inc. Historical Marketcap From 2022 to 2026
Between 2022 and today, MAIA Biotechnology Inc.'s market cap moved from $212.96 Million to $ 77.66 Million, with a yearly change of -27.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $77.66 Million | -16.34% |
| 2025 | $92.83 Million | -22.73% |
| 2024 | $120.13 Million | +69.23% |
| 2023 | $70.99 Million | -66.67% |
| 2022 | $212.96 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 23rd, 2026 the market cap of MAIA Biotechnology Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $77.66 Million USD |
| MoneyControl | $77.66 Million USD |
| MarketWatch | $77.66 Million USD |
| marketcap.company | $77.66 Million USD |
| Reuters | $77.66 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About MAIA Biotechnology Inc.
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illin… Read more